This is a pilot study in which the investigators will investigate the effect of exogenous glucagon on cerebral glucose metabolism in healthy humans.
Participants will participate in either part C or part D of the study, and each participant will åparticipate in three study days. During a study day the participant will receive an intravenous infusion of either glucagon, glucose (in an adjustable rate to match to glucose concentrations during glucagon infusion) or saline. During each study day an 18F-FDG PET/CT scan will be performed to quantify cerebral glucose metabolism during the first part (acute effect) of the glucagon/glucose/saline infusion (part C) or the last part (later effect) of the glucagon/glucose/saline infusion (part D).

开始日期2025-03-01

申办/合作机构

University of Copenhagen

NCT06592261

/ Recruiting临床1期IIT

Human Models of Selective Insulin Resistance: Graded Insulin Suppression Test (GIST) Pilot & Feasibility Study

The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit in which they will undergo a "graded insulin suppression test" ("GIST"). The GIST involves intravenous (into the vein) infusions of octreotide, a medication that turns off the body's own production of insulin, as well as replacement of insulin at two different levels (low and high), with or without replacement of glucagon, and glucose (sugar). The study investigators will check blood sugar levels every few minutes during the procedure to determine the effect of the two different insulin levels. This study will evaluate the GIST in both healthy volunteers and those at higher risk for type 2 diabetes.

开始日期2024-09-16

申办/合作机构

Columbia University

[+2]

NCT06240039

/ Not yet recruitingN/A

Direct Versus Indirect Effect of Amino Acids on Hepatokines in Healthy Subjects and Patients With Non-alcoholic Fatty Liver Disease

Liver hormones are key metabolic regulators and increased in metabolic diseases, including fatty liver disease. The underlying mechanisms driving the elevated levels are currently unknown and presents a major challenge in understanding the interplay between liver hormones and fatty liver disease. The project aims to investigate what stimulates the liver to secrete its hormones and why the secretion is increased in patients with fatty liver disease. The investigator (Associate Prof. Nicolai J Wewer Albrechtsen) will investigate the direct and indirect effects of an amino acid amino infusion on the secretion of hepatokines in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD).

开始日期2024-02-01

申办/合作机构

University of Copenhagen

[+1]

100 项与胰高血糖素相关的临床结果

登录后查看更多信息

100 项与胰高血糖素相关的转化医学

登录后查看更多信息

100 项与胰高血糖素相关的专利（医药）

登录后查看更多信息

8,739

项与胰高血糖素相关的文献（医药）

2025-03-01·NASN school nurse (Print)

Undesignated Glucagon in Schools for the Treatment of Diabetes-Related Hypoglycemia: A 2025 Update

Article

作者: Krecic, Matthew R.

Hypoglycemia will occur on school grounds in students with diabetes who are receiving glucose-lowering drugs. Hypoglycemia may be severe, in which a student is unconscious or comatose. Fast-acting carbohydrates remain the first line of treatment for nonsevere hypoglycemia but preparedness with emergency injectable or intranasal glucagon is ideal. Students may not have their own glucagon devices, so unassigned or undesignated glucagon for use with any student in which glucagon is part of their hypoglycemia treatment plan is critical. Several states have laws permitting undesignated glucagon in schools, and school nurses residing in states without such laws could strongly advocate their state legislators to enact similar laws to ensure students in the nurses’ care have access to this lifesaving treatment.

2025-03-01·DIABETES OBESITY & METABOLISM

Is low‐dose glucagon needed and effective in preventing fasted exercise‐induced hypoglycaemia in type 1 diabetes treated with the MiniMed 780G, an automated insulin delivery system?

Article

作者: Bracken, Richard M. ; Ranjan, Ajenthen Gayathri ; McCarthy, Olivia M. ; Christensen, Merete Bechmann ; Lundemose, Sissel Banner ; Nørgaard, Kirsten ; Holst, Jens Juul ; Laugesen, Christian

Abstract:

Aim:

To evaluate and compare the plasma glucose (PG) response during spontaneous fasted morning moderate‐intensity exercise with and without injection of subcutaneous glucagon in adults with type 1 diabetes (T1D) treated with an automated insulin delivery (AID) system.

Methods:

Ten adults (four female) with T1D (age 50 [42–67] years, diabetes duration: 22 [14–44] years, HbA1c: 55 [47–69] mmol/mol) treated with the MiniMed™ 780G AID system participated in a proof‐of‐concept two‐period, crossover trial. Fasting participants undertook a 45 min bout of continuous moderate‐intensity (~60% V̇O2peak) exercise on a cycle ergometer followed by 1 h of rest. Before exercise, 150‐μg glucagon was administered subcutaneously on visit 1 (GLUC) but not on visit 2 (NO‐GLUC). Temporary target on the AID was activated 15 min before until 15 min after exercise cessation. Blood samples were taken at 5‐ and 15‐min intervals for measuring PG and biomarkers. Data were analysed using paired t tests or repeated measures ANOVA.

Results:

Time in range (3.9–10.0 mmol/L) was 100% on both study visits. No hypoglycaemia (<3.9 mmol/L) occurred in either arm. The GLUC arm had significantly higher mean PG (p = 0.01), area under the PG curve (p = 0.01), coefficient of variation (p < 0.01), peak PG (p = 0.01) and PG at the end of exercise (p < 0.01). No differences in endogenous glucoregulatory hormones were observed between visits.

Conclusion:

Adults with T1D treated with the MiniMed™ 780G can perform spontaneous fasted moderate‐intensity exercise without hypoglycaemia. Therefore, glucagon was not needed for prevention of hypoglycaemia in such situations.

2025-03-01·SEMINARS IN DIALYSIS

The Use of Single Pass Albumin Dialysis and Hemoadsorption in Management of Life‐Threatening Amlodipine Overdose

Article

作者: Hui, Wun Fung ; Choi, Ann Wing Man ; Hon, Kam Lun ; Ku, Shu Wing ; Cheung, Wing Lum

ABSTRACT:

We report the successful application of single pass albumin dialysis (SPAD) and hemoadsorption (HA) in two teenagers with amlodipine poisoning. A 16‐year‐old girl with amlodipine overdose developed refractory shock and lactic acidosis despite multiple inotropes, calcium, insulin, and glucagon infusion. SPAD was initiated 18 h after the incident for 21 h. She improved dramatically and was able to wean off all inotropes 54 h after admission. Another 16‐year‐old girl required extracorporeal membrane oxygenation (ECMO) support after deliberate consumption of 1100‐mg amlodipine. SPAD was initiated 13 h after the incident for 38 h, followed by two more sessions of HA using the Cytosorb column. All inotropes were stopped 18 h after terminating the HA, and ECMO was weaned off 28 h later. There were no major complications during the therapy. Our cases demonstrated that early extracorporeal removal can be considered as an adjunctive therapy in children with life‐threatening amlodipine overdose.

174

项与胰高血糖素相关的新闻（医药）

2025-02-20

·医药地理

【凤采鸾章·博文集】胰高血糖素样肽-1受体激动剂在糖尿病肾病中的研究进展

胰高血糖素样肽-1受体激动剂在糖尿病肾病中的研究进展 Research progress of glucagon-like peptide-1 receptor agonists in diabetic nephropathy 王葳，范瑛，汪年松* (上海交通大学医学院附属第六人民医院肾脏内科，上海 200233) 引用王葳, 范瑛, 汪年松. 胰高血糖素样肽-1受体激动剂在糖尿病肾病中的研究进展[J]. 世界临床药物, 2025, 46(1): 8-13.DOI :10.13683/j.wph.2025.01.002. 作者简介王葳，博士研究生，研究方向：慢性肾脏病诊疗。通信作者：汪年松，主任医师，教授，博士生导师，研究方向：糖尿病肾病、急性肾损伤发病机制和防治。基金项目：国家自然基金面上项目(82270761) ；国家重点研发计划(2023YFC2411803) ；上海市重中之重研究中心建设项目[2022ZZ01002(3)]；上海市进一步加快中医药传承创新发展三年行动计划[ZY(2021-2023)-0205-04] 摘要胰高血糖素样肽-1 受体激动剂(glucagon-like peptide-1 receptor agonist，GLP-1RA) 目前已被广泛用于2 型糖尿病(type 2 diabetes mellitus) 患者的治疗。GLP-1RA 亦有助于改善糖尿病肾病(diabetic nephropathy，DN) 患者的肾脏结局。GLP-1RA 通过抑制炎症反应、降低氧化应激、减轻晚期糖基化终末产物诱导的损伤和改善代谢异常等途径发挥肾脏保护作用，在预防和减缓DN 发生发展方面潜力巨大。现就GLP-1RA 应用于DN 的临床证据和作用机制进行综述，为临床提供参考。关键词胰高血糖素样肽-1 受体激动剂；糖尿病肾病；肾脏保护章节导览 1 GLP-1 与GLP-1R 简介 2 GLP-1RA 简介 2.1 GLP-1RA 短效制剂 2.2 GLP-1RA 长效制剂 3 GLP-1RA 对DN 患者肾脏获益的临床证据 4 GLP-1RA 在DN 中的作用机制 4.1 抑制炎症反应 4.2 降低氧化应激 4.3 减轻晚期糖基化终末产物(advanced glycation end products，AGEs) 诱导的损伤 4.4 改善代谢异常 5 结语文章节选糖尿病肾病(diabetic nephropathy，DN) 是一种以持续性蛋白尿排泄增加，和( 或) 肾小球滤过率(glomerular filtration rate，GFR) 进行性下降为临床特征的慢性疾病，是糖尿病(diabetes mellitus，DM) 常见且严重的并发症之一，在DM 患者中发病率高达30% ～ 40%。DN 为DM 患者心血管疾病的重要预测因素，亦为导致终末期肾病(endstage renal disease) 和患者血液透析或肾移植的主要原因。 DN 传统疗法主要集中于控制血糖、血压及改善脂质代谢等方面，常用药物包括降糖药、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂及盐皮质激素受体拮抗剂等。然而，接受治疗后，许多DN 患者肾功能仍会丧失，最终发展为肾衰竭(kidney failure) 或死亡，故临床亟需有明确肾脏保护作用的药物以进一步改善肾脏结局。近年来，随着对胰高血糖素样肽(glucagon-like peptide，GLP)-1生理功能和GLP-1 受体(glucagon-like peptide-1 receptor，GLP-1R) 机制研究的深入，GLP-1R 激动剂(glucagon-like peptide-1 receptor agonist，GLP-1RA) 逐渐成为治疗DM 及其相关并发症的新兴药物。GLP-1RA 不仅能有效控制血糖，且在改善DN患者肾脏功能方面亦展现出良好优势。 ↑长按二维码阅读原文聚焦药物综合评价促进临床合理用药请看《世界临床药物》！本刊为月刊，大16开。邮发代号4-302，全国各地邮局均可订阅。定价：26元，全年312元。订阅电话：021-62790477-751 订阅传真：021-62473200 订阅邮箱：guohx@pharmadl.com END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

临床结果临床研究临床2期

2025-02-13

·国际糖尿病idiabetes

当我问DeepSeek，GCG/GLP-1双靶和GLP-1单靶有什么不同？

点击“蓝字”关注我们为什么同时激活胰高血糖素（GCG）和胰高糖素样肽-1（GLP-1）受体可能比激活单一靶点更具潜力？双靶点药物是否真能兼顾更强疗效与更低副作用？这些问题的答案，正藏在DeepSeek梳理出的上千篇论文、临床试验数据和机制图谱中。（风险提示：以下回复内容均由DeepSeek生成，不作为专家分析或建议，若有偏差，欢迎指正。）结语通过DeepSeek的文献挖掘与分析，我们清晰地看到了GCG/GLP-1双靶点激动剂与GLP-1单靶点药物的显著差异。双靶点药物不仅继承了GLP-1受体激动剂在降糖和减重方面的优势，还通过激活GCG受体进一步提升了能量消耗和脂代谢调控能力，为代谢疾病的治疗开辟了新的可能性。然而，双靶点激动剂的潜力远不止于此。随着更多临床试验的开展和分子设计的优化，未来我们或许能看到更高效、更安全的双靶点药物问世，甚至可能拓展到非酒精性脂肪肝、心血管疾病等更广泛的适应症。参考文献（上下滑动可查看） [1].Drucker, D. J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metabolism, 27(4), 740-756. [2].Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834-1844. [3].Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. [4].Müller, T. D., et al. (2019). Glucagon-Like Peptide 1 (GLP-1) and Glucagon Receptor Dual Agonism: A Novel Approach to Obesity and Type 2 Diabetes. Molecular Metabolism, 30, 1-13. [5].Ambery, P., et al. (2018). MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Meets Safety and Tolerability Endpoints in a Single-Dose, Healthy Subject Trial. Clinical Pharmacology in Drug Development, 7(7), 736-745. [6].Tillner, J., et al. (2019). A Novel Dual GLP-1/Glucagon Receptor Agonist Promotes Weight Loss and Improves Glycemic Control in Preclinical Models. Diabetes, Obesity and Metabolism, 21(5), 1176-1188. [7].Liraglutide vs. Mazdutide: A Comparative Study in Obesity Management. Journal of Endocrinology and Metabolism, 2023. [8].Phase 3 Clinical Trial Results of Mazdutide in Patients with Type 2 Diabetes and Obesity. Diabetes Care, 2024. [9].Mazdutide in NAFLD/NASH: A Promising Therapeutic Option. Hepatology, 2024. [10].Tan, T., et al. (2020). Dual GLP-1/Glucagon Receptor Agonists: A New Era in Obesity and Diabetes Therapy. Trends in Endocrinology & Metabolism, 31(9), 681-692. [11].Knerr, P. J., et al. (2021). The Role of Glucagon in Energy Expenditure and Fat Metabolism: Implications for Dual GLP-1/Glucagon Agonists. Endocrine Reviews, 42(2), 123-145. [12].Safety Profile of GLP-1/Glucagon Dual Agonists: A Meta-Analysis. Pharmacology & Therapeutics, 2023. [13].Long-Term Safety and Efficacy of Mazdutide in Obesity Management. Obesity Reviews, 2024. [14].GLP-1 Receptor Agonists and Beyond: The Future of Obesity Therapy. Nature Reviews Endocrinology, 2022. [15].Emerging Therapies for NAFLD/NASH: The Role of GLP-1/Glucagon Dual Agonists. Journal of Hepatology, 2023. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：医学界内分泌频道）

临床结果临床研究

2025-01-24

·生物谷

免疫细胞还参与血糖调控？！Science揭示免疫细胞ILC2在禁食与运动时调控血糖的机制

在一项新研究中，来自尚帕利莫基金会的研究人员发现，当身体处于低能量状态——比如间歇性禁食或运动时，免疫细胞会像邮递员一样，在神经系统、免疫系统和激素系统之间传递重要信息，帮助调节血糖水平。这一发现为糖尿病、肥胖和癌症等疾病的治疗开辟了新的途径。相关研究结果发表在2025年1月17日的Science期刊上，论文标题为“Neuronal-ILC2 interactions regulate pancreatic glucagon and glucose homeostasis”。重新思考免疫系统论文通讯作者、尚帕利莫基金会免疫生理学实验室负责人Henrique Veiga-Fernandes说，“几十年来，免疫学主要集中在对抗感染上。但我们现在意识到，免疫系统的作用远比我们想象的要广泛得多。”为了说明这一点，他打了个比喻：“如果把我们的身体比作一个大城市，那么免疫细胞不仅仅是警察（抵御病原体），它们还扮演着邮递员的角色，在各个‘部门’之间传递关键信息。” 葡萄糖：身体的能量货币葡萄糖是一种单糖，是我们大脑和肌肉的主要燃料。维持稳定的血糖水平对我们的生存至关重要，尤其是在禁食或长时间体力活动期间，当能量需求高而食物摄入量低时。传统上，血糖调节被认为是由胰腺产生的两种激素——胰岛素（insulin）和胰高血糖素（glucagon）负责的。前者通过促进细胞摄取葡萄糖来降低血糖，后者则通过向肝脏发出信号，从储存的来源释放葡萄糖来升高血糖。 Veiga-Fernandes和他的团队怀疑还有更多的机制参与其中。“例如，一些免疫细胞可以调节脂肪吸收，而我们近期的研究表明，大脑与免疫系统的互动有助于控制脂肪代谢和肥胖。这让我们思考——神经系统和免疫系统能否协同调节其他关键过程，如血糖水平？” 发现免疫细胞的新任务为了探索这一想法，研究人员在小鼠身上进行了实验。他们使用缺乏特定免疫细胞的基因工程小鼠来观察其对血糖水平的影响。他们发现，缺少一种名为ILC2（innate lymphoid cells type 2，2型固有淋巴细胞）的免疫细胞的小鼠无法产生足够的胰高血糖素，导致它们的血糖水平过低。然而，当将ILC2移植到这些缺陷小鼠体内时，它们的血糖恢复正常，证明了这些免疫细胞在能量不足时稳定葡萄糖水平的关键作用。神经免疫相互作用通过控制胰高血糖素的分泌来调节血糖研究人员原本认为这一切都在肝脏中受到调节，因为胰高血糖素在肝脏中发挥作用。但是，他们的数据却指向了一个更复杂的过程。通过先进的细胞标记技术，他们发现肠道中的ILC2细胞在禁食后会转移到胰腺。这种迁移并不是随机的，而是由神经系统精心策划的。禁食期间，肠道中与大脑相连的神经元释放化学信号，告诉ILC2在几个小时内离开肠道前往胰腺的新“邮政编码”。一旦到达那里，这些免疫细胞就会释放细胞因子——微小的化学信使，指示胰腺细胞产生胰高血糖素，进而向肝脏发出释放葡萄糖的信号。对健康和疾病的影响这项研究表明，神经系统、免疫系统和激素系统之间的对话对于维持血糖平衡至关重要。小鼠与人类共享许多基本的生物系统，这意味着这种器官间的交流也可能发生在人类禁食或运动时。了解ILC2的作用及其在神经系统中的调节，可以帮助我们更好地理解日常生活活动如何支持代谢健康。更重要的是，这一发现可能为管理一系列疾病打开新的大门。例如，癌症研究可以从这些发现中受益，因为某些类型的肿瘤可以劫持身体的代谢过程，利用胰高血糖素增加葡萄糖的产生并促进其生长。此外，平衡血糖对预防肥胖和应对全球糖尿病流行也至关重要，靶向这些神经免疫途径可以提供新的预防和治疗方法。正如Veiga-Fernandes所说，“我们正在窃听以前未被监听的器官之间的对话，这可能会改变我们对许多疾病的理解和治疗方法。”最终，研究人员的目标是利用这些结果来改善针对激素和代谢紊乱的治疗方法，为患者带来更好的生活质量。参考资料： Marko Šestan et al. Neuronal-ILC2 interactions regulate pancreatic glucagon and glucose homeostasis. Science, 2025, doi:10.1126/science.adi3624. 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯~

免疫疗法

100 项与胰高血糖素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	胰高血糖素	H04AA01	DB00040

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病	加拿大	Eli Lilly Canada, Inc.	2019-09-25
低血糖	美国	Eli Lilly & Co.	1960-11-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
1型糖尿病	临床3期	加拿大	Eli Lilly & Co.	2013-09-01
2型糖尿病	临床3期	加拿大	Eli Lilly & Co.	2013-09-01
普通感冒	临床1期	加拿大	Eli Lilly & Co.	2013-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ODP313 (ENDO2022)	N/A	尿崩症 copeptin	-	Glucagon (Healthy Participants)	夢鏇膚遞膚獵鬱積觸製(醖獵簾鏇夢夢襯築蓋獵) = 淵艱積壓鏇築願簾餘鑰築觸繭糧襯壓襯糧遞構 (鹹簾鬱鬱鏇顧鬱鏇鏇鑰, 2.38 ~ 28.03)	积极	2022-11-01
				Glucagon (Patients with Central Diabetes Insipidus)	夢鏇膚遞膚獵鬱積觸製(醖獵簾鏇夢夢襯築蓋獵) = 遞選餘衊簾鹽夢衊鏇顧築觸繭糧襯壓襯糧遞構 (鹹簾鬱鬱鏇顧鬱鏇鏇鑰, 0.21 ~ 1.65)
Baqsimi (ESPE2022)	N/A	HbA1c	68	Baqsimi® 3 mg	蓋衊鹹鬱鹹範壓鑰壓蓋(繭淵鏇壓憲襯鏇顧壓觸) = 21% 衊艱衊憲襯醖範獵鏇窪 (窪鬱憲範築繭蓋窪鹹觸 ) 更多	积极	2022-09-15
ADA2022	N/A	糖尿病	-	Nasal Glucagon	選糧願遞齋鹽醖觸獵壓(範夢齋艱選壓壓廠繭築) = 襯鑰窪獵顧餘衊鹹獵觸積築鏇選廠網餘糧繭衊 (範夢餘憲積鑰繭糧鹽壓 )	-	2022-06-01
ADA2022	N/A	-	-	Intraislet Glucagon (GCGRKOβ-cells-/-)	積選簾製廠築積淵廠鏇(顧衊選網繭願蓋願廠獵) = 醖構艱鑰築鹹醖願簾簾衊鏇襯餘憲選選廠衊構 (膚糧壓製願糧積襯齋積 )	-	2022-06-01
				Intraislet Glucagon (Littermate controls)	積選簾製廠築積淵廠鏇(顧衊選網繭願蓋願廠獵) = 齋繭網範鑰製簾壓築襯衊鏇襯餘憲選選廠衊構 (膚糧壓製願糧積襯齋積 )
EASD2021	N/A	低血糖 type 2 diabetes	-	Nasal Glucagon (NG)	構簾齋鏇衊夢構襯窪願(窪醖遞獵製壓艱鏇鹹餘) = 憲糧餘夢繭鹹觸範網衊醖繭醖網簾觸糧遞鏇餘 (製淵襯壓積鑰鹹簾膚鹽 ) 更多	积极	2021-09-30
				Liquid Stable Glucagon Rescue Pen (GRP)	構簾齋鏇衊夢構襯窪願(窪醖遞獵製壓艱鏇鹹餘) = 顧選網鬱願選壓襯窪繭醖繭醖網簾觸糧遞鏇餘 (製淵襯壓積鑰鹹簾膚鹽 ) 更多
ADA2021	N/A	低血糖	-	Nasal Glucagon	築襯憲遞鏇鬱廠選窪簾(鏇蓋鹽淵鑰鏇選壓艱襯) = 鏇繭範餘觸簾繭築糧繭願獵壓膚築積糧簾顧構 (鑰簾觸餘築鏇襯憲遞獵 )	-	2021-06-01
				Liquid Stable Glucagon Rescue Pen	築襯憲遞鏇鬱廠選窪簾(鏇蓋鹽淵鑰鏇選壓艱襯) = 餘襯淵蓋膚繭壓齋遞鹽願獵壓膚築積糧簾顧構 (鑰簾觸餘築鏇襯憲遞獵 )
ADA2021	N/A	低血糖	-	Nasal Glucagon	簾糧顧廠窪壓構繭築獵(醖襯積齋構網鏇壓窪襯) = 蓋製構鬱憲獵衊襯選夢築襯餘簾獵齋糧構餘觸 (衊餘遞艱夢蓋艱鏇願選 ) 更多	-	2021-06-01
				Reconstituted Injectable Glucagon	簾糧顧廠窪壓構繭築獵(醖襯積齋構網鏇壓窪襯) = 願夢襯鹹鑰願觸構膚構築襯餘簾獵齋糧構餘觸 (衊餘遞艱夢蓋艱鏇願選 ) 更多
NCT03421379 \| NCT03339453 (EASD2020)	N/A	低血糖	-	Nasal glucagon	顧艱壓鏇鬱顧鑰築願夢(遞糧壓襯鬱鹽壓鹽積遞) = 鏇鑰顧遞襯網網壓網齋鏇願鹽構製願積艱顧選 (壓淵觸鑰構膚觸簾廠範 ) 更多	积极	2020-09-24
				Injectable glucagon	顧艱壓鏇鬱顧鑰築願夢(遞糧壓襯鬱鹽壓鹽積遞) = 膚鏇選願遞積膚餘糧鏇鏇願鹽構製願積艱顧選 (壓淵觸鑰構膚觸簾廠範 ) 更多
EASD2020	N/A	-	-	Glucagon infusion	膚鬱網構觸鬱壓餘艱獵(鏇衊遞製艱憲餘構廠齋) = 鑰壓壓鏇範廠製繭襯壓夢觸鬱範膚願鹽願壓鹹 (窪餘構願鏇鏇選遞觸構 ) 更多	-	2020-09-22
				Control (no glucagon)	膚鬱網構觸鬱壓餘艱獵(鏇衊遞製艱憲餘構廠齋) = 顧範鏇鹽壓製鬱製選齋夢觸鬱範膚願鹽願壓鹹 (窪餘構願鏇鏇選遞觸構 ) 更多